📢 New insights and implications for those working on M1 drugs: Recent findings from a sample within the Australian Imaging, Biomarkers and Lifestyle (AIBL) study led by Ying Xia of the Australian CSIRO and Paul Maruff from Cogstate show that loss of cholinergic neurons occur in the asymptomatic or preclinical stage of Alzheimer’s Disease. “Loss of volume in the cholinergic rich areas of the Nucleus Basalis of Meynert occurs in cognitively unimpaired older adults with abnormally high levels of amyloid,” said Maruff. “The rate of this is greater than in adjacent areas of the nucleus basalis that have less cholinergic innervation. Importantly, multivariable modeling indicated that in preclinical AD this loss of cholinergic function was associated more strongly with a decline in attentional functions.” 🔬 These findings provide context for designing studies with compounds promoting acetylcholine neurotransmission and observing any potential AD impacts. 📖 Read the full publication here: https://lnkd.in/egt2FiKM
Cogstate’s Post
More Relevant Posts
-
Translating radiopharmaceuticals is a complex process that requires strong preclinical data. Invicro’s preclinical team collaborates with you to unlock critical insights into pharmacology, radiochemistry, dosimetry & biodistribution. Learn more about our preclinical capabilities in this infographic: https://hubs.ly/Q02c7SXG0 #radiopharmaceuticals #theranostics #oncology #radioligandtherapy #imagingCRO
-
-
Translating radiopharmaceuticals is a complex process that requires strong preclinical data. Invicro’s preclinical team collaborates with you to unlock critical insights into pharmacology, radiochemistry, dosimetry & biodistribution. Learn more about our preclinical capabilities in this infographic: https://hubs.ly/Q02r4l5X0 #radiopharmaceuticals #theranostics #oncology #radioligandtherapy #imagingCRO
-
-
Head of the Inria-Inserm team COMPO (COMPutational pharmacology and clinical Oncology)
📣 New paper out! "Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre- and on-Treatment Prognostic Biomarkers" in American Society for Clinical Pharmacology & Therapeutics' journal Clin Pharm Ther. Using large clinical trial datasets (three phase 2 as train set, N = 533, one phase 3 as test set, N = 354), we developed kML (kinetics - Machine Learning). The main novelty was to model on-treatment longitudinal data of routine circulating biomarkers using #NLME and combine with #ML. Two important applications: 👩🔬 Prediction of individual survival, valuable to clinical oncologists for #personalized #healthcare 💊 Prediction of phase 3 trial success, valuable to #drug #development Thanks to coauthors including Mélanie Karlsen, Abdessamad EL KAOUTARI, Célestin BIGARRÉ, Rene Bruno, Francois Mercier, Candice Jamois https://lnkd.in/eEvqb_jP https://lnkd.in/deACYumW
-
-
InMed's INM-901 is a novel, small molecule drug candidate in development for the treatment of #Alzheimer's disease. Preclinical studies of INM-901 demonstrate neuroprotective effects, reduced #neuroinflammation, an ability to promote the growth of neurites and improvement in behavior, cognitive function and memory. INM-901 may target several biological pathways associated with #AlzheimersDisease with studies indicating it targets CB1, CB2 and PPAR pathways. CEO Eric A. Adams presents InMed's INM-901 program in this video: https://ow.ly/41Ab50SWjN9 $INM
-
New Study: ExoPTEN with siRNA from a new GMP-compliant partner effectively targeted damaged spinal cord tissue in a preclinical study. This highlights ExoPTEN's potential as a therapy for acute spinal cord injuries and marks another step towards scaling up! #ExosomeTechnology #SpinalCordInjury #PrecisionMedicine #RegenerativeMedicine #NanodrugDelivery #ScalingUp https://lnkd.in/decBhcr9
NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
globenewswire.com
-
🔬 Webinar reminder: Applications of Humanized Mouse Models in Preclinical Research 🔬 Don’t forget to join our webinar on the introduction and background of humanized mouse models, focusing on their effective applications in preclinical research for advancing targeted therapies across diseases. 🗓️ Time: Today, 11:00 am PDT or 2:00 pm EDT 📍Register now: https://lnkd.in/gUxZh28W #HumanizedMouseModels #PreclinicalResearch #Geneticallyengineeredmousemodels #Pharmaceuticals #Webinar
Welcome! You are invited to join a webinar: Applications of Humanized Mouse Models in Preclinical Research. After registering, you will receive a confirmation email about joining the webinar.
us06web.zoom.us
-
Gan-Xin Yan, MD, PhD, coauthored a study wherein the rabbit ventricular wedge assay (RVWA) was conducted by Dr. Yan's team at LIMR. The study revealed that in vitro ion channel assays may not consistently identify cardiovascular electrophysiological risks observed in vivo, likely being influenced by tissue drug distribution. The RVWA exhibited a heightened sensitivity in detecting specific proarrhythmic signals of compounds under development. This reaffirms the findings of previous blinded validation studies that the RVWA stands as a potent preclinical drug safety testing method, distinguished by its unmatched sensitivity and specificity. https://bit.ly/3usJGA4
-
-
HMX Pro Pharmacology - Drug Delivery takes you on a visual journey through drug delivery innovation. See antibodies in action as they bind to tumor cell antigens, paving the way for targeted treatments and advancements in patient care. https://buff.ly/3RA1h0J
-
-
The in vivo tool enabling a confident transition to Phase I trials This paper discusses the challenges drug developers face when transitioning from preclinical discovery to clinical trials and proposes expanding the drug development toolbox with humanised mouse models. Download the latest whitepaper to learn more about: - The importance of selecting appropriate starting doses in clinical trials. - Why humanised mice better predict human responses to therapeutics. - How to integrate humanised mice into the drug development process to enhance understanding of drug behaviour, toxicity, and efficacy in humans. Download Whitepaper https://lnkd.in/eq7pVYj6 Brought to you by The Jackson Laboratory #InVivo #DrugDevelopment #DrugDiscovery
-
-
Recognizing the pervasive and systemic reality of multibillion-dollar losses from late-stage clinical trial failures, Predictive Oncology recently announced the expansion of its live-cell tumor platform to de-risk drug discovery and accelerate pipeline development. The company — leveraging its artificial intelligence and machine learning capabilities — is now mining its extensive biobank of cryogenically preserved patient-derived live-cell tumor samples, across 137 different tumor types to account for patient heterogeneity ahead of any clinical phase development work. The ability to accelerate drug development timelines would allow pharmaceutical companies to make critical go/no go decisions, redirect resources or reprioritize R&D efforts more quickly and efficiently. To learn more about how Predictive Oncology has successfully demonstrated its ability to increase the Probability of Technical Success (PTS) by incorporating real-world applications, please visit https://lnkd.in/gvnTrtJ5. For investors, click here https://lnkd.in/gb9BepZA. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech #lifesciences
-
